PAION O.N news, videos and press releases
For more news please use our advanced search feature.
PAION O.N - More news...
PAION O.N - More news...
- EQS-Adhoc: PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults
- EQS-News: PAION AG implements resolved capital reduction
- EQS-News: PAION AG reports on fiscal year 2022
- EQS-News: PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS
- EQS-Adhoc: PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults
- EQS-News: PAION AG: Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing
- EQS-News: PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL
- EQS-News: PAION AG issues statement on planned capital measure
- EQS-Adhoc: PAION AG convenes extraordinary general meeting for capital reductions by redemption and consolidation of shares
- EQS-News: PAION AG announces change in Management Board
- EQS-Adhoc: PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
- EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe
- EQS-News: PAION AG reports financial results for the first nine months of 2022
- EQS-Adhoc: PAION AG raises EBITDA forecast for fiscal year 2022
- EQS-News: PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
- DGAP-News: PAION AG reports financial results for the first half-year 2022
- DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY
- DGAP-News: PAION REPORTS SOLID PROGRESS WITH COMMERCIAL ACTIVITIES IN EUROPE
- DGAP-News: PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS MICHAEL SCHLENK AND GREGOR SIEBERT TO THE SUPERVISORY BOARD
- DGAP-News: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2022
- DGAP-Adhoc: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA
- DGAP-News: PAION AG ANNOUNCES CHANGE IN MANAGEMENT BOARD
- DGAP-News: PAION AG REPORTS ON FISCAL YEAR 2021
- DGAP-News: PAION AG ANNOUNCES CHANGE IN SUPERVISORY BOARD
- DGAP-Adhoc: PAION ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED FUTURE ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP
- DGAP-News: PAION SUBMITS EXTENSION APPLICATION OF MARKETING AUTHORIZATION FOR REMIMAZOLAM IN THE INDICATION GENERAL ANESTHESIA TO THE EUROPEAN MEDICINES AGENCY
- DGAP-News: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2021
- DGAP-News: PAION AG ANNOUNCES INITIATION OF PIVOTAL STUDY OF REMIMAZOLAM (BYFAVO(R)) IN PEDIATRIC PROCEDURAL SEDATION
- DGAP-News: PAION SIGNS EXCLUSIVE UK SUPPLY AND DISTRIBUTION AGREEMENT WITH CLINIGEN
- DGAP-News: PAION LAUNCHES XERAVA(R) (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN THE NETHERLANDS
